| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $4,010,180 | 2 | 67 |
Sells | $9,461 | 1 | 33 |
| DUNTON ALAN W | director | 1 | $4M | 0 | $0 | $4M |
| DEVEER ROBERT K JR | director | 1 | $10,180 | 0 | $0 | $10,180 |
| WILLS STEPHEN T | Executive VP and CFO/COO | 0 | $0 | 1 | $9,461 | $-9,461 |
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
Over the last 12 months, insiders at Palatin Technologies, Inc. have bought $4.01M and sold $9,461 worth of Palatin Technologies, Inc. stock.
On average, over the past 5 years, insiders at Palatin Technologies, Inc. have bought $113.55M and sold $13,705 worth of stock each year.
Highest buying activity among insiders over the last 12 months: DUNTON ALAN W (director) — $4M. DEVEER ROBERT K JR (director) — $10,180.
The last purchase of 1,500 shares for transaction amount of $225M was made by SPANA CARL (President and CEO) on 2025‑06‑13.
| 2025-12-24 | Sale | WILLS STEPHEN T | Executive VP and CFO/COO | 565 0.1977% | $16.74 | $9,461 | +4.38% | |
| 2025-06-13 | SPANA CARL | President and CEO | 1,500 – | $150,000.00 | $225M | +89.10% | ||
| 2025-06-13 | WILLS STEPHEN T | Executive VP and CFO/COO | 1,500 – | $150,000.00 | $225M | +89.10% | ||
| 2025-06-13 | DUNTON ALAN W | director | 200 – | $20,000.00 | $4M | +89.10% | ||
| 2025-05-07 | DEVEER ROBERT K JR | director | 100,000 0.2127% | $0.10 | $10,180 | +91.22% | ||
| 2024-08-01 | Sale | WILLS STEPHEN T | Executive VP and CFO/COO | 4,999 0.0253% | $1.66 | $8,274 | -47.93% | |
| 2024-04-11 | DEVEER ROBERT K JR | director | 6,000 0.0394% | $2.12 | $12,703 | -40.50% | ||
| 2024-03-06 | Sale | DEVEER ROBERT K JR | director | 11,700 0.0789% | $2.00 | $23,434 | -23.66% | |
| 2023-12-06 | Sale | WILLS STEPHEN T | Executive VP and CFO/COO | 4,998 0.0341% | $2.51 | $12,563 | -30.93% | |
| 2023-12-04 | Sale | DUNTON ALAN W | director | 200 0.0014% | $2.48 | $496 | -23.94% | |
| 2022-12-27 | SPANA CARL | President and CEO | 10,000 0.093% | $2.23 | $22,297 | +3.60% | ||
| 2022-12-27 | WILLS STEPHEN T | Executive VP and CFO/COO | 10,000 0.0928% | $2.22 | $22,245 | +3.60% | ||
| 2022-12-21 | Sale | DUNTON ALAN W | director | 200 0.002% | $2.97 | $594 | -16.67% | |
| 2021-07-01 | Hull Joseph Stanley | director | 10,000 0.0041% | $0.61 | $6,100 | -30.65% | ||
| 2021-07-01 | Morris Arlene | director | 33,000 0.0139% | $0.62 | $20,460 | -30.65% | ||
| 2021-06-30 | SPANA CARL | President and CEO | 75,000 0.0319% | $0.62 | $46,394 | -29.51% | ||
| 2021-06-30 | WILLS STEPHEN T | Executive VP and CFO/COO | 75,000 0.0318% | $0.62 | $46,238 | -29.51% | ||
| 2021-06-30 | DUNTON ALAN W | director | 20,000 0.0085% | $0.62 | $12,350 | -29.51% | ||
| 2020-11-18 | DEVEER ROBERT K JR | director | 54,000 0.0215% | $0.41 | $22,140 | +25.00% | ||
| 2020-09-29 | Sale | DEVEER ROBERT K JR | director | 54,000 0.0219% | $0.46 | $24,980 | +14.58% |
| DUNTON ALAN W | director | 224112 0.8618% | $3.55M | 11 | 3 | <0.0001% |
| DEVEER ROBERT K JR | director | 138065 0.5309% | $2.19M | 6 | 2 | <0.0001% |
| WILLS STEPHEN T | Executive VP and CFO/COO | 63488 0.2441% | $1.01M | 10 | 3 | <0.0001% |
| PROQUEST INVESTMENTS LP | 10 percent owner | 5803972 22.318% | $92.02M | 0 | 1 | |
| MARXE AUSTIN W & GREENHOUSE DAVID M | 10 percent owner | 1800000 6.9215% | $28.54M | 0 | 1 | |
| Hull Joseph Stanley | director | 775966 2.9838% | $12.3M | 5 | 0 | <0.0001% |
| Morris Arlene | director | 698666 2.6866% | $11.08M | 2 | 0 | <0.0001% |
| BVF PARTNERS L P/IL | 10 percent owner | 438127 1.6847% | $6.95M | 0 | 7 | |
| SPANA CARL | President and CEO | 293604 1.129% | $4.66M | 11 | 0 | <0.0001% |
| PRENDERGAST JOHN K A | director | 17673 0.068% | $280,205.42 | 1 | 0 | |
| MOLINOFF PERRY B | director | 11000 0.0423% | $174,405.00 | 1 | 0 | |
| HOROVITZ ZOLA P | director | 10500 0.0404% | $166,477.50 | 1 | 0 | |
| TABER ROBERT I | director | 5500 0.0211% | $87,202.50 | 1 | 0 | |
| Hallam Trevor | Exec. VP - R&D | 2500 0.0096% | $39,637.50 | 1 | 0 |
$5,960,789 | 91 | -7.17% | $401.78M | |
$860,541,348 | 82 | -5.10% | $486.42M | |
$5,911,307 | 70 | -1.38% | $403.79M | |
$54,836,085 | 68 | -0.52% | $393.86M | |
$17,468,215 | 46 | 18.85% | $423.91M | |
$24,384,691 | 42 | -30.27% | $429.81M | |
$74,231,875 | 30 | 40.62% | $405.12M | |
$4,306,464 | 21 | 37.34% | $395.83M | |
$112,238,340 | 19 | 39.16% | $479.63M | |
$2,516,932 | 19 | -15.78% | $440.25M | |
$81,667,942 | 12 | -57.54% | $405.25M | |
$112,952,085 | 11 | -19.19% | $392.17M | |
$14,995,689 | 8 | 3.76% | $447.36M | |
Palatin Technologies, Inc. (PTN) | $166,385 | 7 | -23.62% | $412.32M |
$88,549,962 | 5 | -16.91% | $458.56M | |
$12,035,408 | 5 | -37.54% | $385.92M | |
$4,745,999 | 5 | -4.91% | $390.79M | |
$144,224 | 4 | 21.31% | $484.16M | |
$300,016 | 1 | -50.33% | $482.45M |
| Increased Positions | 3 | +30% | 29,964 | +359.07% |
| Decreased Positions | 5 | -50% | 8,345 | -100% |
| New Positions | 3 | New | 29,964 | New |
| Sold Out Positions | 5 | Sold Out | 8,345 | Sold Out |
| Total Postitions | 8 | -20% | 29,964 | +259.07% |